Search
New Origin Biopharma Secures Additional Tens of Millions of Yuan in Series A+ Funding Round
2026-01-21 /
Read about 0 minute
Author：小编
On January 21, 2026, Shenzhen New Origin Biopharma Co., Ltd. made public the successful closure of an additional tens-of-millions-yuan strategic Series A+ funding round. This round saw continued investment from an existing shareholder, the Hong Kong-listed entity XtalPi. The newly acquired funds are earmarked for further advancing the research and development enhancements of the 'DEL+AI' integrated technology platform. Additionally, the investment will expedite the strategic layout and clinical progression of the company's innovative drug pipelines, ultimately boosting efficiency and success rates during the early stages of drug discovery.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
